Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co. has initiated the EMERGE trial, a randomized, double-blind, placebo-controlled pivotal Phase 3 trial to evaluate a single dose of STS101 in the acute treatment of migraine. Co. also has initiated its ASCEND trial, in patients with migraine who will treat their migraine attacks with STS101 on an as-needed basis for up to 12 months. The STSA stock yearly return is shown above.
The yearly return on the STSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the STSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|